C34H32ClNO3S

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: C34H32ClNO3S
• 英文别名: 2-[1-[[3-(2-acetylphenyl)-1-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
• 化学式: C₃₄H₃₂ClNO₃S
• 分子量: 570.1
• InChiKey: DYLOVNSFPNMSRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  40
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  92.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Topical Montelukast formulations
  申请人：TARO PHARMACEUTICAL INDUSTRIES LTD.

  公开号：US11173117B2

  公开（公告）日：2021-11-16

  The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.

  本公开提供了局部乳剂，包含约0.5%至约10%的孟鲁司特或其药学上可接受的盐；以及约0.4%至约4%的卡波姆；其中乳剂中包含孟鲁司特的颗粒的D90小于约50μm，其中孟鲁司特或其药学上可接受的盐均匀地分散在乳剂中，并且乳剂的pH值为约3.0至约6.5。本公开还提供了一种局部凝胶，包含(a)约0.5%至约10%的孟鲁司特或其药学上可接受的盐；(b)约0.2%至约8%的纤维素聚合物；和(c)约80%至约95%的两性化合物；其中凝胶包含小于4%的水。
• Quinoline-containing ketoacids as leukotriene antagonists
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0500360B1

  公开（公告）日：1997-06-25
• PROGRESSIVE EMULSION CRYSTALLIZATION
  申请人：KRKA, D.D., Novo Mesto

  公开号：EP2413911B1

  公开（公告）日：2014-02-19
• PHARMACEUTICAL COMPOSITIONS COMPRISING MONTELUKAST
  申请人：Kappala Ramesh

  公开号：US20090124657A1

  公开（公告）日：2009-05-14

  Pharmaceutical compositions comprising montelukast or pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof.
• TOPICAL MONTELUKAST FORMULATIONS
  申请人：TARO PHARMACEUTICAL INDUSTRIES LTD.

  公开号：US20210236423A1

  公开（公告）日：2021-08-05

  The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.